<DOC>
	<DOCNO>NCT00073762</DOCNO>
	<brief_summary>Primary Objective : To compare antidepressant efficacy safety subject receive DVS-233 SR versus subject receive placebo . Secondary Objective : To assess response subject receive DVS-233 SR clinical global evaluation , functionality , general wellbeing , pain , absence symptom ( Hamilton Psychiatric Rating Scale Depression , 17-item [ HAM-D17 ] less equal 7 ) versus subject receive placebo .</brief_summary>
	<brief_title>Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Outpatients Sexually active woman participate study must use medically acceptable form contraception Subjects must primary diagnosis major depressive disorder 4 Clinical Global ImpressionsSeverity scale ( CGIS ) Treatment DVS233 SR time past Treatment venlafaxine ( immediate release [ IR ] extend release [ ER ] ) within 90 day study day 1 Known hypersensitivity venlafaxine ( IR ER )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>